Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05700461 trial: what clinicians have said so far
Drug Screening Using Novel IMD in Renal Cell Carcinoma
- NCT05700461 ↗
- Recruiting
- Oliver Jonas
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05700461 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05700461 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Renal Cell Carcinoma
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer
- Interventions
- Implantable Microdevice (IMD)
- Arms
- Implantable microdevice (IMD) + Biopsy + Standard of Care Treatment · Experimental
- Enrollment
- 20 (estimated)
- Primary outcomes
- Safety of microdevice implantation
- Number of Patients with Feasible Microdevice Procedure
- Sponsor
- Oliver Jonas with Dana-Farber Cancer Institute
- Start
- Dec 1, 2024
- Primary completion
- Oct 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05700461 · updated May 18, 2026